Our goal: eliminate COVID-19. For good.
Our subsidiary NeuroClear Technologies, Inc. has recently partnered with an accomplished group of pharmaceutical industry veterans to bring to market a solution to the current pandemic.
According to the latest data, estimated 40% to 70% of the global population will be infected with COVID-19 with a rate of infection that is estimated to continue to double every 2 – 10 days based on location. The novel, powerful, orally administered, broad-spectrum anti-viral agent Vicromax(tm) will be developed by our new subsidiary, ViralClear Pharmaceuticals, Inc. Our team is working diligently on bringing to market a safe, efficient solution to address the biggest healthcare crisis in a generation.
Source: Centers for Disease Control and Prevention
Problem: Urgently addressing a truly global challenge
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in 2019 in Wuhan, China, and has since spread globally, resulting in the 2019–20 coronavirus pandemic. While the majority of cases result in mild symptoms, some progress to severe pneumonia and multi-organ failure. The rate of deaths per number of diagnosed cases is on average 3.4%, ranging from 0.2% in those less than 20 to approximately 15% in those over 80 years old*.
As of March 22nd, 2020, there have been 294,110 cases and 12,944 deaths confirmed worldwide. Global spread has been rapid, with 184 countries now having reported at least one case. The last time the world responded to a global emerging disease epidemic of the scale of the current COVID-19 pandemic with no access to vaccines was the 1918-19 H1N1 influenza pandemic, which killed at least 50 million people globally. Even with modern technology and healthcare, experts expect upwards of several million deaths globally as a result of COVID-19.
*Source: World Health Organization
The novel, powerful, orally administered, broad-spectrum anti-viral agent Vicromax(tm) demonstrated strong activity against COVID-19 in cell culture. The product already completed Phase I and three Phase II trials in other indications and underwent extensive animal testing and human clinical experience in patients. We expect that Vicromax(tm) could be used alone or in a combination with other anti-viral agents or immune modulators.
We intend to develop Vicromax(tm) and take it through clinical trials under a new subsidiary ViralClear Pharmaceuticals, Inc.
- Formulation has completed Phase 1 trials and three Phase II trials in other indications.
- The product will be administered orally in easy-to-swallow softgel capsules or liquid formulations
- The small molecule nature of the pharmaceutical allows for it to be scaled rapidly to meet the needs in times of global pandemics.
We will be regularly updating this page to update on our progress.
Media inquiries: firstname.lastname@example.org
*Source: World Health Organization, Centers for Disease Control and Prevention, New York Times, Harvard Global Health Institute